Literature DB >> 32724501

Dose Modification of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis.

Jennie H Best1, Ibrahim Abbass1, Lenore Tominna1, William Reiss1.   

Abstract

Entities:  

Year:  2020        PMID： 32724501      PMCID： PMC7370831     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  10 in total

1.  Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis.

Authors:  Andrew Hresko; Tzu-Chieh Lin; Daniel H Solomon
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-10       Impact factor: 4.794

2.  Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.

Authors:  Kim Lauper; Dan C Nordström; Karel Pavelka; Maria Victoria Hernández; Tore K Kvien; Eirik Klami Kristianslund; Maria Jose Santos; Žiga Rotar; Florenzo Iannone; Catalin Codreanu; Galina Lukina; Sara L Gale; Khaled Sarsour; Yves Luder; Delphine Sophie Courvoisier; Cem Gabay
Journal:  Ann Rheum Dis       Date:  2018-05-05       Impact factor: 19.103

3.  Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.

Authors:  Kim Lauper; Denis Mongin; Florenzo Iannone; Eirik K Kristianslund; Tore K Kvien; Dan C Nordström; Karel Pavelka; Manuel Pombo-Suarez; Ziga Rotar; Maria J Santos; Catalin Codreanu; Galina Lukina; Sara L Gale; Markus John; Yves Luder; Delphine S Courvoisier; Cem Gabay
Journal:  Semin Arthritis Rheum       Date:  2019-06-28       Impact factor: 5.532

4.  Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents.

Authors:  Anagha Nadkarni; Donna McMorrow; Chad Patel; Robert Fowler; David Smith
Journal:  J Comp Eff Res       Date:  2017-08-09       Impact factor: 1.744

5.  Societal cost of rheumatoid arthritis patients in the US.

Authors:  Howard Birnbaum; Crystal Pike; Rebecca Kaufman; Maryna Marynchenko; Yohanne Kidolezi; Mary Cifaldi
Journal:  Curr Med Res Opin       Date:  2010-01       Impact factor: 2.580

6.  Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis.

Authors:  Jennie H Best; Amanda M Kong; Gregory M Lenhart; Khaled Sarsour; Marni Stott-Miller; Yong Hwang
Journal:  J Rheumatol       Date:  2018-01-15       Impact factor: 4.666

7.  Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis.

Authors:  Rajeshwari Punekar; Jeannie Choi; Susan Boklage; Melitza Iglesias-Rodriguez; Kamala Nola
Journal:  Am Health Drug Benefits       Date:  2019-12

8.  Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.

Authors:  Vibeke Strand; Namita Tundia; Yan Song; Dendy Macaulay; Mahesh Fuldeore
Journal:  J Manag Care Spec Pharm       Date:  2018-04

9.  Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.

Authors:  Jacques-Eric Gottenberg; Jacques Morel; Elodie Perrodeau; Thomas Bardin; Bernard Combe; Maxime Dougados; Rene-Marc Flipo; Alain Saraux; Thierry Schaeverbeke; Jean Sibilia; Martin Soubrier; Olivier Vittecoq; Gabriel Baron; Arnaud Constantin; Philippe Ravaud; Xavier Mariette
Journal:  BMJ       Date:  2019-01-24

10.  Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.

Authors:  Kosuke Ebina; Motomu Hashimoto; Wataru Yamamoto; Akira Ohnishi; Daijiro Kabata; Toru Hirano; Ryota Hara; Masaki Katayama; Shuzo Yoshida; Koji Nagai; Yonsu Son; Hideki Amuro; Kengo Akashi; Takanori Fujimura; Makoto Hirao; Keiichi Yamamoto; Ayumi Shintani; Atsushi Kumanogoh; Hideki Yoshikawa
Journal:  PLoS One       Date:  2018-03-15       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.